Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/13/2018 04/16/2018 04/17/2018 04/18/2018 04/19/2018 Date
75.22(c) 74.69(c) 75.47(c) 75.68(c) 74.44(c) Last
4 432 085 4 720 527 4 351 909 3 043 694 3 956 356 Volume
-0.09% -0.70% +1.04% +0.28% -1.64% Change
More quotes
Financials (USD)
Sales 2018 21 287 M
EBIT 2018 11 179 M
Net income 2018 6 735 M
Debt 2018 17 141 M
Yield 2018 2,99%
Sales 2019 21 254 M
EBIT 2019 11 184 M
Net income 2019 7 237 M
Debt 2019 19 765 M
Yield 2019 3,19%
P/E ratio 2018 14,45
P/E ratio 2019 13,69
EV / Sales2018 5,44x
EV / Sales2019 5,57x
Capitalization 98 675 M
More Financials
Company
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need.The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey,... 
Sector
Biotechnology & Medical Research
Calendar
05/01 | 10:01pmEarnings Release
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
04/19GILEAD SCIENCES : Tmunity tops off series A round
AQ
04/19GILEAD SCIENCES : Astellas Announces Sale of Certain Agensys Research Facilities..
PR
04/17GILEAD SCIENCES : to Release First Quarter 2018 Financial Results on Tuesday, Ma..
BU
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/16GILEAD SCIENCES : Report
CO
04/13GILEAD SCIENCES : Presents Data on Multiple Investigational Regimens for the Tre..
BU
04/12GILEAD SCIENCES : An Application for the Trademark "KEEP CREATING" Has Been File..
AQ
04/12GILEAD SCIENCES : Patent Issued for FXR (NR1H4) Modulating Compounds (USPTO 9932..
AQ
04/12GILEAD SCIENCES : An Application for the Trademark "KEEP LOVING" Has Been Filed ..
AQ
04/12GILEAD SCIENCES : Trademark Application for "KEEP EXPRESSING" Filed by Gilead Sc..
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on GILEAD SCIENCES 
GILEAD SCIENCES - 2014
A valuable trading opportunity
BUY
GILEAD SCIENCES - 2014
Continuation of the bullish trend
BUY
More Strategies
Latest Tweets
04/19Investors mull Gilead's filgotinib in wake of Eli Lilly's/Incyte's baricitini.. 
04/19Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug
1
04/19Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug  
04/19$GILD insiders really need to show some conviction… This reminds me of $BSX a.. 
04/19Which drug makers are most vulnerable to a new cost-shifting maneuver by PBMs.. 
More tweets
Qtime:405
News from SeekingAlpha
04/19Investors mull Gilead's filgotinib in wake of Eli Lilly's/Incyte's baricitini.. 
04/19Astellas sells certain U.S. research facilities to Gilead 
04/18READER INQUIRY : Is Recent Weakness In Sangamo Therapeutics A Buying Opportunity.. 
04/17Evelo Biosciences Files For U.S. IPO 
04/17JF'S CORE BIOTECH BUYS #11 : Positive News For Several Holdings, A Change To Ben.. 
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 89,0 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Norbert W. Bischofberger CSO, Executive VP-Research & Development
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES5.35%98 675
VERTEX PHARMACEUTICALS10.10%41 476
REGENERON PHARMACEUTICALS-14.19%34 613
GENMAB15.65%12 876
BEIGENE LTD (ADR)73.08%9 059
BLUEBIRD BIO INC-1.88%8 735